NovelStem International Corp (NSTM)

[CollinsIR]

$HOLL transformation into Stem Cell Diagnostic Investment (NovelStem International Corp.)

Is intended to position shareholders for substantial upside as the tech developer NewStem Ltd. advances its technology toward commercialization. With very substantial potential and target markets and the potential enhance patient care and reduces costs for chemotherapy treatments - NewStem could become worth much more than it's current $10M post money valuation (we've all seen biotech valuations many times that - so it's certainly possible if things progress).

That's the idea - and the upside from the Netco Partners 50% interest remains with current holders. We do IR work for HOLL so let us know if you'd like to learn more or be added their distribution list.

Link to Press Release